Page last updated: 2024-11-11

neuromedin c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

neuromedin C: decapeptide isolated from porcine spinal cord; corresponds to the C-terminal decapeptide of gastrin-releasing peptide; bombesin-like peptide; RN given refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5486814
MeSH IDM0121296

Synonyms (20)

Synonym
81608-30-2
neuromedin c
gastrin releasing peptide[18-27]
grp-10,frog
bdbm85492
gastrin releasing peptide 10
grp-10
bombesin decapeptide
gly-asn-his-trp-ala-val-gly-his-leu-met-nh2
canine gastrin-releasing peptide 10
gastrin releasing peptide (18-27)
grp (18-27)
AKOS015902708
DTXSID50231221
neuromedin c (porcine)
mfcd00167608
grp (18-27) (human, porcine, canine)
neuromedin
neuromedin c (trifluoroacetate salt)
AKOS040755524

Research Excerpts

Overview

Neuromedin C (NMC) is a decapeptide that acts as a growth factor in a wide range of tumors. These include carcinomas of the pancreas, stomach, breast, prostate, and colon.

ExcerptReferenceRelevance
"Neuromedin C (NMC) is a decapeptide (Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH(2)) that acts as a growth factor in a wide range of tumors including carcinomas of the pancreas, stomach, breast, prostate, and colon. "( Neuromedin C: potential-dependent surface-enhanced Raman spectra in the far-red spectral region on silver, gold, and copper surfaces.
Niaura, G; Podstawka-Proniewicz, E; Proniewicz, LM, 2010
)
3.25
"Neuromedin C is a bombesin-like neuropeptide of the sequence Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2. "( Neuromedin C binds Cu(II) and Ni(II) via the ATCUN motif: implications for the CNS and cancer growth.
Harford, C; Sarkar, B, 1995
)
3.18

Treatment

Neuromedin C treatment increased latency to feeding, decreased food intake, decreased the time spent feeding and their ratio. Treatment caused larger and more frequent increases in [Ca(2+)](i) than those triggered by neuromedin B.

ExcerptReferenceRelevance
"Neuromedin C treatment increased latency to feeding, decreased food intake, decreased the time spent feeding and their ratio, the number and the duration of feeding episodes during the first 5 min, without modifying body temperature or stereotype activity."( Neuromedin C microinjected into the amygdala inhibits feeding.
Bagi, EE; Fekete, EM; Lénárd, L; Tóth, K, 2007
)
2.5
"Treatment with neuromedin C caused larger and more frequent increases in [Ca(2+)](i) than those triggered by neuromedin B, with 96% and 78% of cells responding, respectively."( Identification and characterisation of functional bombesin receptors in human astrocytes.
Marshall, IC; Mason, S; McKnight, A; McNulty, S; Skepper, JN; Smart, D, 2002
)
0.65

Dosage Studied

ExcerptRelevanceReference
" A dose-response relationship was observed, with maximal stimulation of phagocytic process between 10(-12)M and 10(-9)M."( Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C.
De la Fuente, M; Del Rio, M; Ferrandez, MD; Hernanz, A, 1991
)
0.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (121)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (31.40)18.7374
1990's53 (43.80)18.2507
2000's14 (11.57)29.6817
2010's16 (13.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.18 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.78%)4.05%
Observational0 (0.00%)0.25%
Other125 (97.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]